Factors affecting antimicrobial resistance in Streptococcus pneumoniae following vaccination introduction
ER Watkins, A Kalizang'Oma, A Gori, S Gupta… - Trends in …, 2022 - cell.com
Streptococcus pneumoniae is a major cause of pneumonia, meningitis, and septicaemia
worldwide. Pneumococcal antimicrobial resistance (AMR) has been highlighted by the WHO …
worldwide. Pneumococcal antimicrobial resistance (AMR) has been highlighted by the WHO …
Association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral …
Importance An association between pneumococcal nasopharyngeal carriage and invasive
pneumococcal disease (IPD) has been previously established. However, it is unclear …
pneumococcal disease (IPD) has been previously established. However, it is unclear …
Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines
Q Du, W Shi, D Yu, K Yao - Human Vaccines & …, 2021 - Taylor & Francis
The universal administration of pneumococcal conjugate vaccines (PCVs) had been
demonstrated as an effective way to prevent Streptococcus pneumoniae infection. However …
demonstrated as an effective way to prevent Streptococcus pneumoniae infection. However …
Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an …
Background Invasive pneumococcal disease remains an important health priority owing to
increasing disease incidence caused by pneumococci expressing non-vaccine serotypes …
increasing disease incidence caused by pneumococci expressing non-vaccine serotypes …
Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome …
Background Serotype 24F is one of the emerging pneumococcal serotypes after the
introduction of pneumococcal conjugate vaccine (PCV). We aimed to identify lineages …
introduction of pneumococcal conjugate vaccine (PCV). We aimed to identify lineages …
Limited indirect effects of an infant pneumococcal vaccination program in an aging population
M van der Linden, M Imöhl, S Perniciaro - PloS one, 2019 - journals.plos.org
Background A general recommendation for adult pneumococcal vaccination with 23-valent
polysaccharide vaccine (PPV23) for adults 60 and older has been in place in Germany since …
polysaccharide vaccine (PPV23) for adults 60 and older has been in place in Germany since …
Pathogen-and type-specific changes in invasive bacterial disease epidemiology during the first year of the COVID-19 pandemic in the Netherlands
A Steens, MJ Knol, W Freudenburg-de Graaf… - Microorganisms, 2022 - mdpi.com
COVID-19 control measures have resulted in a decline in invasive bacterial disease caused
by Neisseria meningitidis (IMD), Streptococcus pneumoniae (IPD), and Haemophilus …
by Neisseria meningitidis (IMD), Streptococcus pneumoniae (IPD), and Haemophilus …
[HTML][HTML] Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults …
Background Streptococcus pneumoniae causes pneumococcal disease, and older adults
are at an increased risk. Sequential vaccination of 13-valent pneumococcal conjugate …
are at an increased risk. Sequential vaccination of 13-valent pneumococcal conjugate …
Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of …
N Ouldali, E Varon, C Levy, F Angoulvant… - The Lancet Infectious …, 2021 - thelancet.com
Background The long-term benefits of pneumococcal conjugate vaccines (PCVs) remain
unknown because of serotype replacement. We aimed to estimate the effect of PCV …
unknown because of serotype replacement. We aimed to estimate the effect of PCV …
Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation
R Cohen, C Levy, N Ouldali, M Goldrey… - Clinical Infectious …, 2021 - academic.oup.com
We aimed to assess the invasive disease potential of non-PCV13 serotypes after the
implementation of this vaccine. Most non-PCV13 serotypes had low invasive disease …
implementation of this vaccine. Most non-PCV13 serotypes had low invasive disease …